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Background: Nebulization times have been identified as an issue in patient compliance with tobramycin solution for inhalation (TSI) therapy in
cystic fibrosis (CF).
Methods: In this randomized, open-label, multicentre, two-period, crossover study, patients (n=25) with CF and chronic pulmonary pseudomonal
infection received TSI for 15 days via eFlow rapid or LC PLUS nebulizer. Nebulization times and sputum/serum tobramycin concentrations were
determined, and safety evaluated.
Results: Nebulization times were significantly shorter for eFlow rapid versus LC PLUS on Day 1 (least squares mean estimate of the difference
−10.5 min, 95% confidence intervals [CI] −12.6, −8.3, pb0.0001) and Day 15 (difference −7.7 min, 95% CI −9.0, −6.5, pb0.0001). Broadly
comparable sputum/systemic exposure to tobramycin was observed and the incidence of adverse events was similar for both nebulizers.
Conclusion: Use of the eFlow rapid nebulizer reduced TSI nebulization time. The systemic exposure to tobramycin appeared to be broadly similar
in this exploratory study.
© 2009 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Tobramycin solution for inhalation; Cystic fibrosis; Chronic infection; Nebulization; Pharmacokinetics; Pseudomonas aeruginosa1. Introduction
Outcomes in patients with cystic fibrosis and chronic pulmo-
nary pseudomonal infection can be improved by the daily use of
nebulized anti-pseudomonal antibiotics, especially tobramycin☆ Previous presentation of data. A summary of the results of this trial have been
posted to the Novartis Clinical Trial Results Database. The data have been
presented previously as a poster at the 30th European Cystic Fibrosis Conference
(ECFC), 13–16 June 2007, Belek, Turkey.
⁎ Corresponding author. Tel.: +44 1403 324658; fax: +44 1403 323060.
E-mail address: pearl.kho@novartis.com (P. Kho).
1569-1993/$ - see front matter © 2009 European Cystic Fibrosis Society. Publishe
doi:10.1016/j.jcf.2009.07.001[1]. The current standard-of-care is nebulized tobramycin solu-
tion for inhalation 300mg in 5ml (TSI; TOBI®, Novartis Pharma
AG) [2]. This solution is specifically formulated for the lung in
terms of osmolality and pH to facilitate the delivery of high con-
centrations of the antibiotic to the site of infection in the endo-
bronchial space, while minimizing the systemic exposure and
organ toxicities associated with parenteral aminoglycosides
[3]. Intermittent TSI twice daily is effectively administered via
a nebulizer, and there is a substantial body of published evi-
dence showing that it is well tolerated, improves pulmonary
function, decreases sputum density of Pseudomonas aeruginosa,
and reduces the incidence of hospitalizations in children andd by Elsevier B.V. All rights reserved.
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tion [1,4–7].
A long nebulization time may adversely impact on adherence
to the regimen [8]. In the case of the PARI LC® PLUS jet nebu-
lizer (PARI GmbH, Starnberg, Germany), powered by the De-
Vilbiss Pulmo-Aide® compressor (DeVilbiss, Philadelphia, USA),
the typical time to deliver the recommended 300 mg dose of
tobramycin is 12–15 min [9]. In patients with cystic fibrosis,
there is a need for faster [10], more convenient delivery systems,
particularly because of the regular use of multiple drugs and in-
haled products. One such approach currently in development
is tobramycin inhalation powder, a novel dry-powder formula-
tion designed to deliver a high payload of tobramycin topically
to the lungs [11]. Alternatively, faster nebulization times may be
achieved by more rapid nebulization or the use of more concen-
trated solutions. PARI GmbH have developed the PARI eFlow®
rapid nebulizer [12], a highly efficient and fast method to ad-
minister inhaled medications [13]. The eFlow rapid nebulizer is
a soft-mist electronic device designed to deliver liquid solution
and suspension products using a vibrating membrane to generate
an aerosol with a high percentage of droplets in the respirable
size range.
The present study was performed to evaluate the nebulization
time, sputum and serum pharmacokinetics and safety of tobra-
mycin delivered as TSI via the eFlow rapid nebulizer compared
with the LC PLUS nebulizer (the nebulizer currently approved
for the delivery of TSI).
2. Methods
2.1. Study subjects
Eligible patients (≥6 years of age) had confirmed cystic
fibrosis (sweat chloride≥60 mEq/l by the quantitative pilocar-
pine iontophoresis test and/or genotype with twomutations, plus
clinical signs and symptoms) and proven chronic P. aeruginosa
colonization of the lungs. Other inclusion criteria were: ability to
expectorate sputum; forced expiratory volume in 1 s (FEV1)≥
25% of calculated value based on age, gender and height [12];
and clinically stable and able to tolerate 1weekwithout aminogly-
coside treatment. The exclusion criteria were: receipt of inhaled
or intravenous colistin or other aminoglycosides≤7 days before
TSI administration; receipt of loop diuretics≤7 days before TSI
administration; haemoptysisN60 cm3≤30 days before TSI ad-
ministration; and renal impairment (serum creatinine or blood
urea above the upper limit of normal for sex and age or an ab-
normal urine analysis defined as ≥2+ proteinuria on routine
dipstick testing).Written informed consent was required from all
patients or legal representatives.
2.2. Study design
This exploratory, randomized, open-label, multicentre, two-
period, crossover study was performed after a 1-week screening
period. In both study periods, patients received tobramycin
300 mg (in the form of TSI 60 mg/ml) twice daily, the approved
dose of TSI for patients with cystic fibrosis, for 2 weeks (Days1–14) plus one TSI dose in the morning of Day 15. Each 15 day
treatment was delivered via either the eFlow rapid or the LC
PLUS nebulizer. After a 1-week TSI-free phase, patients re-
ceived TSI delivered by the alternative nebulizer for a further
15 days as per the randomized crossover design. Patients were
followed for 1 week after the completion of the two TSI admin-
istration periods. Compliance was determined by evaluation of
the quantity of returned TSI at the end of the study and by diaries
completed by the patients. The study, whichwas approved by the
institutional review board of each participating centre, conformed
to the ethical principles of the Declaration of Helsinki.
2.3. Evaluation of nebulization time and pharmacokinetics
Nebulization times (time from the first tidal breath after the
nebulizer was activated until no more TSI could be aerosolized)
were recorded on Days 1 and 15 in the clinic and on other days
by patients in diaries provided. Nebulization is complete when
the nebulizer becomes dry and automatically stops (eFlow ra-
pid) or when the nebulizer begins to splutter and nebulization is
stopped manually (LC PLUS). Patients attended at clinic on
Days 1 and 15, of both study periods, to determine first-dose and
steady-state pharmacokinetics of tobramycin in sputum and
serum. Sputum samples were expectorated with deep coughing,
after gargling with 30 ml of normal saline, twice for 5–10 s, to
avoid contamination of the sputum sample with inhaled tobra-
mycin in the buccal cavity. Sputum samples were collected im-
mediately before the start of nebulization (0 h) and 0.5, 1.5, 2 and
8 h after completion of nebulization. Venous blood samples were
collected immediately before the start of nebulization (0 h) and
0.5, 1, 1.5, 2, 4 and 8 h after completion of nebulization.
Tobramycin concentration in sputum was determined by
reversed-phase high-performance liquid chromatography on a
Nova-Pac C18 4 µm (150×3.9 mm) column at room tempera-
ture using an isocratic elution (water/acetonitrile [39/61, volume/
volume] with 0.2% glacial acetic acid) at a flow rate of 1.5 ml/
min, with ultraviolet detection at 360 nm. The lower limit of
quantification was 20 µg/g. Tobramycin concentration in serum
was determined by fluorescence polarization immunoassay, with
a lower quantification limit of 0.05 µg/ml [14]. The area under
the tobramycin concentration–time curves (sputum and serum)
from 0 to 8 h after the start of nebulization (AUC0–8), maximum
tobramycin concentrations (Cmax), and time to Cmax (Tmax) were
determined using standard non-compartmental methods.
The accumulation ratio was the geometric mean ratio of
AUC0–8,Day 15:AUC0–8,Day 1.
2.4. Safety evaluation
The following three criteria were used to assess safety: (1)
potential for systemic toxicity, defined as unusually high con-
centrations of serum tobramycin (N2 µg/ml in samples collected
prior to treatment [trough], N12 µg/ml in samples collected 1 h
after completion of nebulization [Cmax], and N4 µg/ml in any
other sample); (2) incidence of clinically significant bronchos-
pasm, defined as ≥20% decrease in FEV1 observed from pre-
dose to 30 min after completion of nebulization; and (3)
Table 2
Tobramycin sputum (n=21) and serum (n=22) pharmacokinetics for tobra-
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upper tobramycin serum concentration cut-offs (2 and 12 µg/ml)
were selected before the start of the study and were based on
levels commonly used to guide intravenous tobramycin use. The
cut-off of 4 µg/ml was chosen based on our previous pharma-
cokinetic studies in which serum levels rarely exceeded this
value. Other investigators have also used this cut-off as a safety
signal [15].
2.5. Statistical analysis
Our intent in this exploratory study was to look for trends in
nebulization time and pharmacokinetic parameters produced by
the two nebulizers in a representative number of patients; hence,
there was no formal statistical basis for the size of the patient
population. We performed a post-hoc random-effect analysis of
variance (ANOVA) to assess the devices' effects on nebulization
time and tobramycin Cmax and AUC0–8 (log-transformed). For
nebulization times, results were expressed as the least squares
mean estimates of the difference (eFlow rapid—LC PLUS) with
associated 95% confidence intervals (CI). For pharmacokinetic
parameters, the least squares mean estimates of the device ratio
(eFlow rapid:LC PLUS) with associated 90% CIs were gener-
ated in conformance with conventional bioequivalence statis-
tical testing [16].
3. Results
3.1. Characteristics of study subjects
Of the 26 patients enrolled, one patient from the LC PLUS/
eFlow rapid randomization group was excluded because of a
serious adverse event after randomization, but prior to commen-
cing any TSI treatment. Thus, the protocol defined intent-to-treat
population comprised 25 subjects (Table 1). To be evaluable
for pharmacokinetics analysis, patients must have received the
first and at least the last four doses of tobramycin in both study
periods (to ensure steady-state serum and sputum tobramycinTable 1
Demographic characteristics of the study population.
Characteristic eFlow rapid/
LC PLUS
LC PLUS/
eFlow rapid
(n=13) (n=12)
Age (years)
Mean±SD 27.6±6.3 24.6±3.9
Range 22–44 19–32
Male (n [%]) 7 (54) 8 (67)
Weight (kg)
Mean±SD 54.0±5.8 51.9±8.3
Range 46–62 39–65
Height (cm)
Mean±SD 164.4±7.0 166.3±12.2
Range 155–180 146–187
Inhaled tobramycinN7 days before study, n (%) 6 (46) 4 (33)
Inhaled colistin in previous 2 months, n (%) 4 (31) 4 (33)
Mean±SD percentage predicted FEV1 59.8±22.7 52.6±20.2
FEV1, forced expiratory volume in 1 s; SD, standard deviation.levels on Day 15) and provided the associated pharmacokinetic
serum and sputum samples. On the basis of these criteria, 22
patients were included in the pharmacokinetic population for
evaluation of serum data and 21 patients for evaluation of sputum
data as well as nebulization time. There were no changes in stan-
dard therapy in any patient, and no other antibiotic treatment was
initiated during the study. Patient compliance with the treatment
regimen was 98.4±2.7% and 96.6±6.4% for eFlow rapid in
periods 1 and 2, respectively, and 99.1±2.1% and 97.1±4.6% for
LC PLUS in periods 1 and 2, respectively.
3.2. Nebulization times
Mean total TSI nebulization times using eFlow rapid and LC
PLUS, respectively, were 7.4±1.7 and 17.6±4.0 min on Day 1,
and 9.2±5.1 and 16.0±2.8min onDay 15 for the evaluable phar-
macokinetic population (n=21). One patient in the PK evaluable
population did not have a record of nebulization time due to
treatment interruption. On both occasions, nebulization times
were significantly shorter for eFlow rapid; on Day 1 the least
squares mean estimate of the difference was −10.5 min (95%
CI −12.6, −8.3, pb0.0001) and on Day 15 the difference was
−7.7 min (95% CI −9.0, −6.5, pb0.0001).
3.3. Sputum tobramycin concentrations
Sputum pharmacokinetic parameters after a single dose
(Day 1) and at steady state are summarized in Table 2. Steady-
state concentration–time profiles on Day 15 are shown in Fig. 1.
Sputum levels of tobramycin were highly variable: coefficients
of variation exceeded 100% for both the eFlow rapid and the
LC PLUS nebulizers. Against this variable background, the
mean sputum exposure was comparable for the two nebulizers
on Day 1 with geometric mean ratios (eFlow rapid:LC PLUS)
close to unity: forCmax 1.08 (90%CI 0.72, 1.62) and for AUC0–8mycin solution for inhalation delivered via the eFlow rapid or LC PLUS
nebulizer.
Pharmacokinetic
parameter
Day 1 Day 15
eFlow rapid LC PLUS eFlow rapid LC PLUS
Sputum
C0 (μg/g) – – 148±354 65±107
Cmax (μg/g) 981±1191 754±927 1572±2182 769±823
Tmax (h) 0.5 (0.5–2) 0.5 (0.5–1.5) 0.5 (0.5–2) 0.5 (0.5–2)
AUC0–8 (μg·h/g) 1688±2046 1511±1744 3731±7235 1941±2301
Accumulation ratio – – 3.7±4.9 2.1±3.1
Serum
C0 (μg/ml) – – 0.1±0.2 0.1±0.1
Cmax (μg/ml) 0.7±0.6 0.9±0.5 1.2±1.0 1.3±0.7
Tmax (h) 0.75 (0.5–2) 1.0 (0.5–2) 0.5 (0.5–1.5) 0.5 (0.5–1)
AUC0–8 (μg·h/ml) 2.6±2.5 3.6±1.3 4.8±3.5 5.1±2.6
Accumulation ratio – – 2.9±3.4 1.4±0.5
AUC, area under the concentration–time curve; C0, pre-dose trough concentra-
tions; Cmax, maximum tobramycin concentrations, Tmax, time to Cmax.
Values are arithmetic mean ±standard deviation except for Tmax where data are
expressed as median (range).
Fig. 1. Mean sputum tobramycin concentrations over time onDay 15 after admin-
istration of tobramycin solution for inhalation via the eFlow rapid or LC PLUS
nebulizer (pharmacokinetic evaluable population). Bars represent the 95% confi-
dence intervals. Includes one patient with an eFlow rapid:LC PLUSAUC0–8 ratio
of 37.7.
Fig. 2. Mean serum tobramycin concentrations over time on Day 15 after admin-
istration of tobramycin solution for inhalation via the eFlow rapid or LC PLUS
nebulizer (pharmacokinetic evaluable population). Bars represent the 95% con-
fidence intervals.
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after the first dose, were achieved in a median time of 0.5 h
(range 0.5–2) with both the eFlow rapid and LC PLUS nebu-
lizers (Table 2). At steady state onDay 15, pre-dose trough sputum
concentrations were highly variable: values of 148±354 µg/g
and 65±107 µg/g were recordedwith eFlow rapid and LCPLUS,
respectively. Based on AUC0–8,Day 15:AUC0–8,Day 1 ratios in the
sputum, tobramycin accumulated 3.7-fold with eFlow rapid and
2.1-fold with LC PLUS (Table 2). On Day 15, tobramycin con-
centration in sputum with eFlow rapid was higher by nearly
2-fold compared with LC PLUS, with a geometric mean ratio of
1.83 (90% CI 1.29, 2.60) for Cmax and 1.78 (90% CI 1.06, 2.98)
for AUC0–8. On Day 15, the majority of patients (n=16) had a
higher Cmax from eFlow rapid compared with LC PLUS. This is
reflected in the concentration plots in Fig. 1 and is likely attri-
butable to the fact that the dose was administered over a shorter
time by eFlow rapid. The majority of eFlow rapid:LC PLUS
AUC0–8 ratios on Day 15 were between 0.5 and 2; however, an
extreme outlier had a value of 37.7. In this patient AUC0–8 was
12 µg h/g and 456 µg h/g via the LC PLUS and eFlow rapid,
respectively. Both values were near the lower end of the range for
this parameter in the population as a whole; hence, the relative
increase did not lead to an extreme absolute exposure in this
patient.
3.4. Serum tobramycin concentrations
Serum tobramycin pharmacokinetic parameters after a single
dose (Day 1) and at steady state are summarized in Table 2.
Steady-state concentration–time profiles on Day 15 are shown
in Fig. 2. After the first dose, the geometric mean ratios (eFlow
rapid:LC PLUS) for Cmax and AUC0–8 were 0.59 (90% CI 0.45,
0.78) and 0.55 (90% CI 0.40, 0.75), respectively. Though mean
accumulation ratios (assessed as AUC0–8,Day 15:AUC0–8,Day 1)
were 2.9 and 1.4 for eFlow rapid and LC PLUS respectively,
pre-dose trough serum tobramycin concentrations (C0) on Day
15 were low (around 0.1 µg/ml) for both devices indicatingaccumulation is minimal. On Day 15, the geometric mean ratios
(eflow rapid:LC PLUS) for Cmax and AUC0–8 were 0.83 (90%
CI 0.62, 1.11) and 0.86 (90% CI 0.63, 1.16), respectively.
3.5. Safety
Predefined serum concentration thresholds for potential sys-
temic toxicity were not exceeded in any patient when TSI was
delivered by either the eFlow rapid or the LC PLUS nebulizer.
Specifically, Cmin ranged from 0 to 0.5 µg/ml for eFlow rapid
and 0 to 0.3 µg/ml for LC PLUS. Cmax ranged from 0.1 to
3.9 µg/ml for eFlow rapid and 0.4 to 2.7 µg/ml for LC PLUS.
No clinically significant bronchospasm was reported in any
patient receiving TSI via either the eFlow rapid or the LC PLUS
nebulizer: mean changes (±SD) in FEV1 from pre-dose to 30min
post-dose on Day 15 were −1.3±9.9% with the eFlow rapid
nebulizer and −2.8±6.2% with the LC PLUS nebulizer. As
patients had previously received TSI, significant improvements
in FEV1 were not expected. Adverse events, all mild to moderate
in intensity and transient, were reported by 19 subjects when
receiving TSI via the eFlow rapid nebulizer and by 16 patients
when receiving TSI via the LC PLUS nebulizer. When using the
eFlow rapid nebulizer, the main events experienced were head-
ache (32%), cough (12%), and dyspnoea (12%). The main events
experienced when using the LC PLUS nebulizer were headache
(28%) and abdominal pain (12%). No patient discontinued treat-
ment due to an adverse event.
4. Discussion
This exploratory crossover study in patients with cystic fibro-
sis and chronic pseudomonal colonization of the lungs demon-
strated that administration of TSI via the eFlow rapid nebulizer
significantly (pb0.0001) reduced nebulization time by approxi-
mately one half. Patients with chronic pseudomonas endobron-
chial infections often have complicated, time-consuming treatment
regimens and maintaining long-term adherence is challenging.
336 D. Hubert et al. / Journal of Cystic Fibrosis 8 (2009) 332–337The development of new delivery systems that lower treatment
burden time may help improve adherence and it is speculated
that this could potentially translate into better clinical response
and quality of life. The increased speed of delivery achievable
with the eFlow rapid nebulizer plus the added benefits of easy
handling and portability may all encourage patient adherence
[8]. In the present study both devices were associated with good
adherence as required by the protocol. The study provided no
evidence that the faster nebulization improved adherence; longer-
term clinical trials are required to provide additional information
regarding differences in patient adherence with the two nebu-
lizers. To date, the clinical efficacy of TSI delivered by the two
different nebulizers has not been compared in a large clinical
trial, and the use of TSI in association with the eFlow rapid
nebulizer is not currently approved by any regulatory body.
The intent of this study was also to characterize tobramycin
systemic exposure and sputum concentration from TSI via the
two nebulizers and to explore trends in the data that might reveal
potential differences between the devices which would warrant
further evaluation. This study was not statistically powered to
test for equivalence in serum pharmacokinetic parameters, and
results suggest that systemic tobramycin exposure in serum with
eFlow rapidwas broadly similar to that observed from LC PLUS,
particularly at steady state.
As with other studies [11], sputum pharmacokinetic data
were difficult to interpret. Although the sputum exposure of
tobramycin appeared to be numerically higher with the eFlow
rapid nebulizer, especially at steady state, interpretation of
sputum concentrations after inhalation with the two nebulizers
was hindered by the high variability, including an extreme
value. The variability in sputum tobramycin concentrations
observed in this and other studies [11] is likely the result of
individual differences in inhalation patterns, airway obstruction,
mucus plugging, and other patient-specific factors. During
inhalation of TSI using any nebulizer, the active drug reaches
the site of bacterial infection within the lungs virtually
immediately; clinically effective concentrations are achieved
in the endobronchial space. Using either nebulizer, the maximal
concentration of tobramycin in sputum greatly exceeded
tobramycin minimum inhibitory concentrations (MICs), which
have been shown to vary between 0.5 and 32 mg/l for isolates
obtained from patients with cystic fibrosis treated with once- or
three-times-daily intravenous tobramycin and an MIC90 (MIC
required to inhibit the growth of 90% of organisms) of 16 mg/l
after TSI treatment [17,18]. On the other hand, some
investigators consider that a high sputum concentration could
be a reflection of a high deposition in the upper airways and thus
less deposition in the lower airways. Further studies would be
required to determine the clinical relevance of any potentially
higher sputum concentrations using the eFlow rapid device.
Despite previously expressed concern that inhaled tobramy-
cin may induce transient bronchospasm [3], our study provided
no evidence that the use of the eFlow rapid nebulizer to admin-
ister TSI resulted in any increase in clinically significant bron-
chospasm. The overall incidence of treatment-emergent adverse
events, which were as expected in this patient population [4–7],
was similar whether TSI was delivered via the eFlow rapid orLC PLUS nebulizer. Further evidence supporting the safety of
TSI administered via the eFlow rapid nebulizer is derived from
the absence of any pre-dose or peak concentration of tobra-
mycin in serum exceeding thresholds of 2 and 12 µg/ml, respec-
tively. Long-term studies are required to fully characterize the
safety profile of TSI delivered via the eFlow rapid nebulizer.
In conclusion, the present study has shown that delivery of
TSI via the eFlow rapid nebulizer is quicker than the same dose
of TSI administered via the LC PLUS. The systemic exposure
and sputum concentration of tobramycin from eFlow rapid and
LC PLUS appeared to be broadly similar in this exploratory study.
In addition, the eFlow rapid and LC PLUS nebulizers have com-
parable safety profiles. Whether the trends in tobramycin dispo-
sition would translate into a clinical advantage for eFlow rapid
versus LC PLUS requires a larger comparative trial in patients
with cystic fibrosis.
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